• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The usefulness of arbekacin compared to vancomycin.阿贝卡星相对于万古霉素的有用性。
Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1663-6. doi: 10.1007/s10096-011-1490-9. Epub 2011 Nov 29.
2
Comparison of Arbekacin and Vancomycin in Treatment of Chronic Suppurative Otitis Media by Methicillin Resistant Staphylococcus aureus.阿贝卡星与万古霉素治疗耐甲氧西林金黄色葡萄球菌所致慢性化脓性中耳炎的比较
J Korean Med Sci. 2015 Jun;30(6):688-93. doi: 10.3346/jkms.2015.30.6.688. Epub 2015 May 13.
3
Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA.万古霉素和阿贝卡星联合治疗耐甲氧西林金黄色葡萄球菌引起的感染性心内膜炎取得成功。
Jpn J Antibiot. 2011 Dec;64(6):389-94.
4
A Multicentre, Open label, Randomized, Comparative, Parallel Group, Active-controlled, Phase III Clinical Trial to Evaluate Safety and Efficacy of Arbekacin Sulphate Injection versus Vancomycin Injection in Patients Diagnosed with MRSA Infection.一项多中心、开放标签、随机、对照、平行组、活性药物对照的III期临床试验，旨在评估硫酸阿贝卡星注射液与万古霉素注射液在确诊为耐甲氧西林金黄色葡萄球菌（MRSA）感染患者中的安全性和有效性。
J Assoc Physicians India. 2018 Dec;66(12):47-50.
5
Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus.基于阿贝卡星的联合用药对万古霉素异质性中介金黄色葡萄球菌的协同作用。
J Korean Med Sci. 2006 Apr;21(2):188-92. doi: 10.3346/jkms.2006.21.2.188.
6
Intrathoracic irrigation with arbekacin for methicillin-resistant Staphylococcus aureus empyema following lung resection.肺切除术后耐甲氧西林金黄色葡萄球菌脓胸的阿贝卡星胸腔内灌洗治疗
Interact Cardiovasc Thorac Surg. 2012 Sep;15(3):437-41. doi: 10.1093/icvts/ivs285. Epub 2012 Jun 20.
7
[Appropriate use of anti-methicillin-resistant Staphylococcus aureus agents in a retrospective study].[一项回顾性研究中抗耐甲氧西林金黄色葡萄球菌药物的合理使用]
Yakugaku Zasshi. 2008 Jul;128(7):1073-9. doi: 10.1248/yakushi.128.1073.
8
[Vancomycin and arbekacin, drugs of treatment for MRSA infections].[万古霉素和阿贝卡星，耐甲氧西林金黄色葡萄球菌感染的治疗药物]
Nihon Rinsho. 1992 May;50(5):1054-9.
9
Characterization of beta-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR) in a patient with septicemia during long-term vancomycin administration.在长期万古霉素治疗期间发生败血症的患者中，β-内酰胺类抗生素诱导的万古霉素耐药性金黄色葡萄球菌（BIVR）的特征。
J Infect Chemother. 2009 Oct;15(5):274-8. doi: 10.1007/s10156-009-0703-y. Epub 2009 Oct 24.
10
Perioperative antimicrobials in chest surgery patients positive for methicillin-resistant Staphylococcus aureus.
Gen Thorac Cardiovasc Surg. 2010 Dec;58(12):657-9. doi: 10.1007/s11748-009-0582-2. Epub 2010 Dec 18.

引用本文的文献

1
Clinical Efficacy and Safety of Arbekacin against Pneumonia in Febrile Neutropenia: A Retrospective Study in Patients with Hematologic Malignancies.阿贝卡星治疗发热性中性粒细胞减少症患者肺炎的临床疗效与安全性：一项针对血液系统恶性肿瘤患者的回顾性研究
Infect Chemother. 2022 Mar;54(1):80-90. doi: 10.3947/ic.2021.0126.
2
A Systemic Literature Review and Meta-Analysis Reporting the Prevalence and Impact of Methicillin-Resistant Infection in India.一项关于印度耐甲氧西林感染的患病率及影响的系统文献综述和荟萃分析
Infect Dis (Auckl). 2020 Nov 5;13:1178633720970569. doi: 10.1177/1178633720970569. eCollection 2020.
3
Arbekacin as an Alternative Drug to Teicoplanin for the Treatment of MRSA Infection.阿贝卡星作为替考拉宁治疗耐甲氧西林金黄色葡萄球菌感染的替代药物。
Yonsei Med J. 2016 Jul;57(4):1047-8. doi: 10.3349/ymj.2016.57.4.1047.
4
Clinical Usefulness of Arbekacin.阿贝卡星的临床应用价值
Infect Chemother. 2016 Mar;48(1):1-11. doi: 10.3947/ic.2016.48.1.1. Epub 2016 Mar 31.
5
Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.阿贝卡星用于血液系统恶性肿瘤患者高危感染的临床疗效与安全性。
Int J Hematol. 2016 Mar;103(3):334-40. doi: 10.1007/s12185-015-1926-6. Epub 2015 Dec 29.
6
Comparison of Arbekacin and Vancomycin in Treatment of Chronic Suppurative Otitis Media by Methicillin Resistant Staphylococcus aureus.阿贝卡星与万古霉素治疗耐甲氧西林金黄色葡萄球菌所致慢性化脓性中耳炎的比较
J Korean Med Sci. 2015 Jun;30(6):688-93. doi: 10.3346/jkms.2015.30.6.688. Epub 2015 May 13.
7
Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.阿贝卡星：一种用于治疗耐甲氧西林金黄色葡萄球菌和多重耐药革兰氏阴性病原体所致感染的新型药物。
Clin Pharmacol. 2014 Sep 26;6:139-48. doi: 10.2147/CPAA.S44377. eCollection 2014.
8
Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.印度南部阿贝卡星、头孢米诺、磷霉素、比阿培南及其他抗生素对革兰氏阴性临床分离株的最低抑菌浓度分布测定：一项前瞻性研究。
PLoS One. 2014 Jul 28;9(7):e103253. doi: 10.1371/journal.pone.0103253. eCollection 2014.
9
The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue MRSA infection: preliminary study.阿贝卡星与万古霉素治疗皮肤及软组织耐甲氧西林金黄色葡萄球菌感染的疗效及安全性：初步研究
Infect Chemother. 2013 Mar;45(1):62-8. doi: 10.3947/ic.2013.45.1.62. Epub 2013 Mar 29.

本文引用的文献

1
Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007.韩国产 ceftazidime 和氟喹诺酮类耐药肺炎克雷伯菌和亚胺培南耐药不动杆菌属的增加：来自 2005 年和 2007 年 KONSAR 研究数据的分析。
Yonsei Med J. 2010 Nov;51(6):901-11. doi: 10.3349/ymj.2010.51.6.901.
2
Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006.2001 年至 2006 年韩国医院万古霉素中介金黄色葡萄球菌菌株的全国监测研究。
J Microbiol Biotechnol. 2010 Mar;20(3):637-42.
3
Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.住院患者初始万古霉素浓度-时间曲线与肾毒性之间的关系。
Clin Infect Dis. 2009 Aug 15;49(4):507-14. doi: 10.1086/600884.
4
Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007.1997 - 2007年美国重症监护病房耐甲氧西林金黄色葡萄球菌中心静脉导管相关血流感染情况
JAMA. 2009 Feb 18;301(7):727-36. doi: 10.1001/jama.2009.153.
5
International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008.国际医院感染控制协会报告，2002 - 2007年数据总结，2008年1月发布。
Am J Infect Control. 2008 Nov;36(9):627-37. doi: 10.1016/j.ajic.2008.03.003. Epub 2008 Oct 3.
6
Arbekacin.
Int J Antimicrob Agents. 1995 Jul;5(4):227-30. doi: 10.1016/0924-8579(95)00014-y.
7
Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.2002 - 2006年美国耐万古霉素金黄色葡萄球菌
Clin Infect Dis. 2008 Mar 1;46(5):668-74. doi: 10.1086/527392.
8
Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus.阿贝卡星治疗耐甲氧西林金黄色葡萄球菌感染患者的药代动力学-药效学关系
Antimicrob Agents Chemother. 2006 Nov;50(11):3763-9. doi: 10.1128/AAC.00480-05.
9
Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.一所大学医院在5年期间金黄色葡萄球菌临床分离株的万古霉素最低抑菌浓度升高。
J Clin Microbiol. 2006 Nov;44(11):3883-6. doi: 10.1128/JCM.01388-06. Epub 2006 Sep 6.
10
Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model.在体外感染性心内膜炎模型中，万古霉素、阿贝卡星和庆大霉素单独或联合使用对耐甲氧西林金黄色葡萄球菌的疗效。
Antimicrob Agents Chemother. 2003 Dec;47(12):3768-73. doi: 10.1128/AAC.47.12.3768-3773.2003.

阿贝卡星相对于万古霉素的有用性。

The usefulness of arbekacin compared to vancomycin.

机构信息

The Department of Pharmacy, Chonbuk National University Hospital, and The Department of Preventive Medicine, Chonbuk National University Medical School, Jeonju, Jeonbuk, South Korea.

出版信息

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1663-6. doi: 10.1007/s10096-011-1490-9. Epub 2011 Nov 29.

DOI:10.1007/s10096-011-1490-9
PMID:22124537
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3364417/
Abstract

The bacteriological efficacy response (improved, arbekacin vs. vancomycin; 71.2% vs. 79.5%) and clinical efficacy response (improved, arbekacin vs. vancomycin; 65.3% vs. 76.1%) were not statistically different between the two groups. The complication rate was significantly higher in the vancomycin group (32.9%) compared to the arbekacin group (15.1%) (p=0.019). Arbekacin was not inferior to vancomycin, and it could be a good alternative drug for vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) treatment.

摘要

两组间的细菌学疗效反应（改善，阿贝卡星 vs. 万古霉素；71.2% vs. 79.5%）和临床疗效反应（改善，阿贝卡星 vs. 万古霉素；65.3% vs. 76.1%）无统计学差异。万古霉素组的并发症发生率（32.9%）明显高于阿贝卡星组（15.1%）（p=0.019）。阿贝卡星并不逊于万古霉素，对于耐甲氧西林金黄色葡萄球菌（MRSA）的治疗，它可能是万古霉素的一种替代药物。